首页> 美国卫生研究院文献>International Scholarly Research Notices >Application of Hydrotropic Solubilization in Spectrophotometric Estimation of Lornoxicam from Tablets
【2h】

Application of Hydrotropic Solubilization in Spectrophotometric Estimation of Lornoxicam from Tablets

机译:亲水增溶在片剂中氯诺昔康分光光度估算中的应用

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Lornoxicam is a selective cyclooxygenase-1 and cyclooxygenase-2 inhibitor that exhibits anti-inflammatory, analgesic, and antipyretic activities. It is used in osteoarthritis and rheumatoid arthritis; and in treatment of postoperative pain and primary dysmenorrhoea. Lornoxicam is completely insoluble in water but soluble in alkaline solutions. Hydrotropic solubilization is a technique used to increase the aqueous solubility of poorly water-soluble drugs and the present study was aimed at developing a hydrotropic technique to increase the solubility of lornoxicam, using 2 M sodium benzoate as the hydrotropic agent. Beer's law was obeyed in the concentration range of 4–24 μg/mL at 381 nm. The solubility of lornoxicam in distilled water considerably increased with the addition of a hydrotropic agent. The analysis of tablets indicated good correlation between the amounts estimated and label claim. The LOD and LOQ of lornoxicam were found to be 0.34 μg/mL and 1.038 μg/mL, respectively, indicating good sensitivity of the proposed method. The percentage recovery was found to be 99.99%–100.21%. Thus the proposed method is new, simple, environmentally friendly, accurate, and cost effective and can be successfully employed in routine analysis of lornoxicam in tablets.
机译:氯诺昔康是一种选择性的环氧合酶1和环氧合酶2抑制剂,具有抗炎,镇痛和解热的活性。它用于骨关节炎和类风湿关节炎;并用于治疗术后疼痛和原发性痛经。氯诺昔康完全不溶于水,但溶于碱性溶液。水溶性增溶是一种用于增加水溶性差的药物的水溶性的技术,本研究旨在开发一种水溶性技术以使用2 M苯甲酸钠作为亲水剂来增加氯诺昔康的溶解性。在381 nm处的浓度范围为4–24μg/ mL,遵守比尔定律。通过添加水溶助长剂,氯诺昔康在蒸馏水中的溶解度大大增加。片剂的分析表明,估计的数量与标签声明的数量之间具有良好的相关性。氯诺昔康的LOD和LOQ分别为0.34μg/ mL和1.038μg/ mL,表明该方法灵敏度高。发现回收率是99.99%–100.21%。因此,所提出的方法是新的,简单的,环境友好的,准确的和成本有效的,并且可以成功地用于片剂中氯诺昔康的常规分析中。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号